South Korea-based medical AI solutions development company VUNO has obtained approval from the Ministry of Food and Drug Safety (MFDS) for its AI-based cardiac arrest prediction software, VUNO Med–DeepCARS as an Innovative Medical Device.
The software is specialized in predicting the risk of cardiac arrest and performs a medical analysis of vital signs of patients in general wards stored in the electronic medical records (EMR) including heart rate, respiratory rate, blood pressure, and body temperature. The collection of data forms the basis for predicting the likelihood of an emergency cardiac arrest situation occurring within the next 24 hours.
Clinical testing is underway for VUNO Med–DeepCARS based on a clinical trial plan approved by the MFDS in June.
According to a research paper published in Critical Care Medicine (CCM) in February, VUNO Med–DeepCARS had a level of sensitivity twice as high as Modified Early Warning Score (MEWS) – a conventional way of cardiac arrest prediction – for the same number of alarms.
THE LARGER TREND
VUNO also recently announced that it was selected to be part of a project, which is led by the National IT Industry Promotion